Drugs / naveglitazar
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00065312 | — | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | naveglitazar | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00065312 ↗ |
| Known as | LY-519818 | ChEMBL registry synonym — accepted as the source's own label CHEMBL181954 ↗ |
| Known as | LY-9818 | ChEMBL registry synonym — accepted as the source's own label CHEMBL181954 ↗ |
| Action | Activate | “Peroxisome proliferator-activated receptor alpha agonist” CHEMBL181954 ↗1“Peroxisome proliferator-activated receptor gamma agonist” CHEMBL181954 ↗ |
| Modality | Small molecule | — CHEMBL181954 ↗ |
| Target | PPARA | “Peroxisome proliferator-activated receptor alpha agonist” CHEMBL181954 ↗ |
| Target | PPARG | “Peroxisome proliferator-activated receptor gamma agonist” CHEMBL181954 ↗ |